The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Alternating non-cross-resistant multiagent chemotherapy (ANCRC) and high-dose chemotherapy followed by autologous stem cell support (HDC-ASCS) in first remission to improve outcome in patients with T-cell lymphoma.
Potjana Jitawatanarat
No relevant relationships to disclose
Richa Dawar
No relevant relationships to disclose
Kaweesak Chittawatanarat
No relevant relationships to disclose
Nicolas Batty
No relevant relationships to disclose
Myron Stefan Czuczman
No relevant relationships to disclose
Francisco J. Hernandez-Ilizaliturri
No relevant relationships to disclose